Balyasny Asset Management
UTHR icon

Balyasny Asset Management’s United Therapeutics UTHR Stock Holding History

Balyasny Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,500
Closed -$13.6M – 3587
2025
Q3 		$13.6M Buy
+32,500
New +$10.9M 0.02% 898
2022
Q3 		– Sell
-26,000
Closed -$6.13M – 3280
2022
Q2 		$6.13M Buy
+26,000
New +$5.29M 0.02% 850

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Balyasny Asset Management's UTHR Position: Q1 2026 in Review

Balyasny Asset Management reduced its United Therapeutics (UTHR) stake by 35% in Q1 2026, selling an estimated $9.62M and leaving 36,623 shares worth $21.7M. The position accounts for 0.03% of the portfolio, ranked #656.

Balyasny Asset Management first reported a position in UTHR in Q4 2015 and has held it in 22 quarters since. The position peaked at $61.6M in Q3 2025. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Balyasny Asset Management held 36,623 shares of United Therapeutics worth $21.7M as of Q1 2026.
  • Balyasny Asset Management sold 19,311 United Therapeutics shares in Q1 2026, an estimated $9.62M.
  • United Therapeutics made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #656 holding.
  • Balyasny Asset Management first reported a position in United Therapeutics in Q4 2015 and has held it in 22 quarters since.
  • Balyasny Asset Management's United Therapeutics position peaked at $61.6M in Q3 2025.
  • 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.